CRUSH Project: Stribild PEP Substudy

Open-label, single-arm trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by University of California, San Francisco. Primary endpoints: Proportion of Young Men Who Have Sex With Men (YMSM) Who Test Positive for HIV at Enrollment at 1 year, Proportion of HIV-positive Enrolled YMSM Who Are Retained, on Therapy, and Who Have Achieved Viral Suppression at 1 year and 2 more. Started May 2013; status: completed.